Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis

Liver International

Volumn 30, Issue 3, 2010, Pages 430-437

  Zachou, Kalliopi ^a,b   Yurdaydin, Cihan ^c   Drebber, Uta ^d   Dalekos, George N ^b   Erhardt, Andreas ^e   Cakaloglu, Yilmaz ^f   Degertekin, Halil ^g   Gurel, Selim ^h   Zeuzem, Stefan ⁱ   Bozkaya, Hakan ^c   Schlaphoff, Verena ^a   Dienes, Hans P ^d   Bock, Thomas C ^j   Manns, Michael P ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF THESSALY   (Greece)

^c ANKARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF COLOGNE   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f ISTANBUL UNIVERSITY   (Turkey)

^g DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^h ULUDAG UNIVERSITY   (Turkey)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

Chronic hepatitis delta; HDV RNA; PCR; Quantitative HBsAg

Indexed keywords

ADEFOVIR DIPIVOXIL; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADOLESCENT; ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELTA AGENT HEPATITIS; FEMALE; GERMANY; GREECE; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TURKEY (REPUBLIC); VIREMIA;

ADOLESCENT; ADULT; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RNA, VIRAL; VIREMIA; YOUNG ADULT;

EID: 77950615079     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02140.x     Document Type: Article

References (38)

1. Farci P. Delta hepatitis: an update. J Hepatol 2003, 39((Suppl. 1)):S212-9.
2. Sagnelli E, Felaco FM, Filippini P. Influence of HDV infection on clinical, biochemical and histological presentation of HBsAg positive chronic hepatitis. Liver 1989, 9:229-34.
3. Fattovich G, Giustina G, Christensen E. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European concerted action on viral hepatitis (Eurohep). Gut 2000, 46:420-6.
4. Rizzetto M. The delta agent. Hepatology 1983, 3:729-37.
5. Taylor JM. Hepatitis delta virus. Virology 2006, 344:71-6.
6. Hadziyannis SJ. Review: hepatitis delta. J Gastroenterol Hepatol 1997, 12:289-98.
7. Wu JC, Chen CM, Sheen IJ. Evidence of transmission of hepatitis D virus to spouses from sequence analysis of the viral genome. Hepatology 1995, 22:1656-60.
8. Niro GA, Casey JL, Gravinese E. Intrafamilial transmission of hepatitis delta virus: molecular evidence. J Hepatol 1999, 30:564-9.
9. Radjef N, Gordien E, Ivaniushina V. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004, 78:2537-44.
10. Dalekos GN, Zervou E, Karabini F, Tsianos EV. Prevalence of viral markers among refugees from southern Albania: increased incidence of infection with hepatitis A, B and D viruses. Eur J Gastroenterol Hepatol 1995, 7:553-8.
11. Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk J Gastroenterol 2006, 17:25-34.
12. Gaeta GB, Stroffolini T, Chiaramonte M. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000, 32:824-7.
13. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection - not a vanishing disease in Europe! Hepatology 2007, 45:1331-2.
14. Rizzetto M. Hepatitis: the comeback? Liver Int 2009, 29((Suppl. 1)):140-2.
15. Romeo R, Del Ninno E, Rumi M. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009, 136:1629-38.
16. Niro GA, Ciancio A, Gaeta GB. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006, 44:713-20.
17. Castelnau C, Le Gal F, Ripault MP. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006, 44:728-35.
18. Erhardt A, Gerlich W, Starke C. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006, 26:805-10.
19. Yurdaydin C, Bozkaya H, Gurel S. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002, 37:266-71.
20. Yurdaydin C, Bozkaya H, Onder FO. Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon. J Viral Hepat 2008, 15:314-21.
21. Aslan N, Yurdaydin C, Wiegand J. Cytotoxic CD4-positive T cells in viral hepatitis. J Viral Hepat 2006, 13:505-14.
22. Aslan N, Yurdaydin C, Bozkaya H. Analysis and function of delta-hepatitis virus-specific cellular immune responses. J Hepatol 2003, 38:15-6.
23. Manns MP, Meyer S, Wedemeyer H. The German network of excellence for viral hepatitis (Hep-Net). Hepatology 2003, 38:543-4.
24. Ishak K, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-9.
25. Saldanha J, Gerlich W, Lelie N. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001, 80:63-71.
26. Rodella A, Galli C, Terlenghi L. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006, 37:206-12.
27. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994, 19:1331-6.
28. Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. Nucleic Acids Res 2002, 30:1292-305.
29. Le Gal F, Gordien E, Affolabi D. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005, 43:2363-9.
30. Yamashiro T, Nagayama K, Enomoto N. Quantitation of the level of hepatitis delta virus RNA in serum, by real-time polymerase chain reaction - and its possible correlation with the clinical stage of liver disease. J Infect Dis 2004, 189:1151-7.
31. Iloeje UH, Yang HI, Su J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-86.
32. Sakugawa H, Nakasone H, Nakayoshi T. Hepatitis B virus concentrations in serum determined by sensitive quantitative assays in patients with established chronic hepatitis delta virus infection. J Med Virol 2001, 65:478-84.
33. Su CW, Huang YH, Huo TI. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006, 130:1625-35.
34. Manesis EK, Schina M, Le Gal F. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther 2007, 12:381-8.
35. Niro GA, Ciancio A, Tillman HL. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005, 22:227-32.
36. Hadziyannis SJ, Sherman M, Lieberman HM, Shafritz DA. Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers. Hepatology 1985, 5:544-7.
37. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004, 99:1160-74.
38. Rousselet MC, Michalak S, Dupre F. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005, 41:257-64.